Brooke molecular phenotypic omics tools to promote the new crown pneumonia symptoms for a Long time (Long COVID) and the research progress of metabolic abnormalities after the acute phase

Perth, Australia, on May 20, 2021.A new crown pneumonia on phenotype and subsequent phenotype transformation of clinical research found that new crown pneumonia in the acute phase after three months, patients in the molecular features of the blood sample appeared briefly and persistent systemic change.Through a combination of nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS detection platform, the above quantitative test of biochemical abnormalities in the tag, found its new crown pneumonia with sustained long-term symptoms (Long COVID).Long-term symptoms persist after acute infection, even if in infection after 6 months, may also affect more than half of the new champions league rehabilitation in patients with pneumonia.

Murdoch university of Australia's national phenotypic group learning center (ANPC) in collaboration with other academic medical centers, brooke (Nasdaq: BRKR) as the main technology partners, recently announced and published a series of new crown in plasma of patients with acute disease and acute pneumonia syndrome is the study of molecular phenotypic group of the late seminal paper (The original link).

Quantitative nuclear magnetic resonance (NMR) and mass spectrum detection platform (only for the use of research), reveals the new crown metabolic abnormalities caused by pneumonia, acute metabolic markers and the interaction of cytokines, as well as the interaction of lipoprotein and inflammatory markers.The platform can create more phenotypic transition markers detection method, significant changes of these markers in the course of disease development.The molecular phenotypic omics detection method can measure the extent of the patients recovered, or the emergence of new chronic PACS risks, such as new diabetes and atherosclerosis, and new and other persistent or to symptoms, including chronic fatigue, "brain fog (brain fog)" and many other new crown pneumonia symptoms for a long time have been reported.

For new crown pneumonia of hospital and patients with mild acute phase after the follow-up study shows that most of patients did not return to normal after three months of biochemical state of health or normal.PACS, also known as the "new champions league pneumonia symptoms for a Long time (Long COVID)" persistent, characterized by persistent symptoms after an acute infection and functional health disorders.More than 57% of patients within six months after the acute phase of one or more symptoms, and phenotypic transition detection based on nuclear magnetic resonance (NMR) and mass spectrum method reveals many metabolic abnormalities were present.

Murdoch university health future research institute vice President and director of ANPC, Jeremy Nicholson professor explained: "advanced nuclear magnetic resonance (NMR) and mass spectrum of plasma screening for complex system model of the new champions league pneumonia provides complementary insights.In the follow-up of patients, we found that they have a variety of partial restoration phenotype,, there are a variety of different biochemical abnormalities.We also noticed that most of the follow-up whether or not there is still a new crown pneumonia patients symptoms, there are metabolic abnormalities, but patients with symptomatic on statistical biochemical abnormalities are more likely to occur in ".

He continued: "this is a very dangerous disease, it not only has claimed many lives, and as we have found, even for the initial symptoms are relatively mild cases, new crown pneumonia may be in the future for a long time for some patients have serious health consequences."

Most of the patients in the acute phase after three months have various blood metabolic abnormalities, in six months had symptoms and there are still different asymptomatic metabolic conditions.The researchers found that the new crown pneumonia patients in the blood plasma lipoprotein changed during infection, closer to commonly found in patients with diabetes and atherosclerosis model.Some abnormal situation in the follow-up of patients, and is reversible, and associated with the liver, energy metabolism and neuropathy markers can not be completely reversed.

ANPC early research results are in agreement with the latest research results, according to a new crown pneumonia is a multiple organ effects of systemic disease.Based on plasma lipoprotein and metabolic phenotype transformation on the map of molecular biomarkers phenotype, can on the progress of the disease, severity and treatment were evaluated.This highlights the influence on the rehabilitation of patients for PACS and long-term health risks of longitudinal study is of great importance.

ANPC designed a new type of relaxation and diffusion edit nuclear magnetic resonance (NMR) method, improve the selectivity of the signal, and thus found the new type of phospholipids signal from super molecular mass.Prof Nicholson adds: "this is editing, dynamics of complex plasma spectra in order to improve the diagnostic program, the first example of selective and other nuclear magnetic resonance (NMR) method on the basis of molecular dynamics and the concentration of developing diagnostic program opened the door."

Brooke applications, industrial and clinical department's chief technology officer Manfred Spraul Dr Commented: "these findings highlight the nuclear magnetic resonance (NMR) and mass spectrometry analysis of integrated platform in PACS screening of potential risk.Our research methods for personalized molecular phenotypic characterization is robust and can be transferred, thus to understand the new crown pneumonia long-term effect provides a better way.Insights in the phenotype of these molecules is expected to support a better new crown pneumonia patients after the acute phase of management, to speed up the recovery of the patients, and to reduce health care costs."

New crown phenotype transformation and phenotypic recovery is characterized by pneumonia by nuclear magnetic resonance (NMR) and mass spectrometry analysis, they for heart disease, metabolic disease, diabetes, kidney disease, liver function, nervous system effects and provides supplementary insights into potential biomarkers of inflammation.

Brooke is Europe to the integration of nuclear magnetic resonance (NMR) + mass spectrometry validation of determination method of clinical research, to develop PACS personalized risk screening and longitudinal monitoring of patients with clinical diagnosis method.

Located in BilbaoCIC bioGUNELead researcher Oscar Millet Dr Commented: "as one of precision medical major clinical research laboratory in Europe, we believe that with the aid of high-performance nuclear magnetic resonance (NMR) and mass spectrometry of PACS research has great potential.We are international led ANPC an active member of the new champions league pneumonia research network.Using ANPC and brooke developed standardized procedures and unified research methods, we will be able to queue in patients with Spain was studied by means of PACS, and on the analysis and biological level with the data of ANPC cross validation."

These studies using the integrated in a second biological safety laboratory ANPC Avance ™ IVDr nuclear magnetic resonance (NMR) metabolic analysis system, and the brook and CIC bioGUNE in vitro diagnostic nuclear magnetic resonance (NMR) research (IVDr) technique.ANPC for molecular characterization of the lab is equipped with the most advanced mass spectrometer, including brooke Impact II and TimsTOF ™ Pro QTOF - MS, and a solariX ™ MRMS system.

User relationship maintenance:

Miroslava Minkova
Senior Director of Investor Relations &
Corporate Development
T: x1479 + 1 (978) 663-3660
E:Investor.Relations@bruker.com

Media contact head:

Thorsten Thiel, Ph. D.
The VP of Group Marketing
Bruker BioSpin
T: + 49 (721) 5161-6500
E:thorsten.thiel@bruker.com

1. Kimhofer T, Lodge S, Whiley L et al. The Integrative Modeling of policy Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS - CoV ‑ 2 Infection,J Proteome Res 2020 Nov 6;19 (11) : 4442-4454
2. Nitschke Lodge S, P, Kimhofer T, et al. The NMR Spectroscopic Windows on the Systemic Effects of SARS - CoV - 2 Infection on Plasma Lipoproteins and Metabolites in base to Circulating Cytokines.Journal of Proteome Research, 2020 (in Chinese). 20, 1382-1396. https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00876
3. Nitschke Lodge S, P, Kimhofer T, et al. The coursing together - and Relaxation - Edited Proton NMR Spectroscopy of 2 Plasma Reveals a High雷竞技怎么下载 - Fidelity Supramolecular Biomarker Signature 3 of SARS - CoV ‐ 2 Infection Analytical Chemistry, 2021.https://dx.doi.org/10.1021/acs.analchem.0c04952
4. Nathan g. Lawler et al. The Systemic Perturbations in Amine and Kynurenine Metabolism Associated with Acute SARS - CoV - 2 Infection and Inflammatory Cytokine Responses, the Journal of Proteome Research (March 16, 2021).DOI: 10.1021 / acs. Jproteome. 1 c00052
5. Elaine Holmes, Julien Wist, et al. Incomplete Systemic Recovery and Metabolic Phenoreversion in Post - Acute - Phase Nonhospitalized COVID - 19 Patients: Implications for Assessment of Post - Acute COVID - 19 Syndrome, Journal of Proteome Research (May 19, 2021).https://pubs.acs.org/doi/10.1021/acs.jproteome.1c00224

This study by Spinnaker health research foundation, McCusker, foundation and the western Australian state sponsorship.